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R enal anemia,  an important complication of chronic kidney disease (CKD),  has been reported 
to have a major effect on the occurrence of cardiovas-
cular events [1].  For the treatment of renal anemia,  
erythropoietin (EPO),  an erythropoiesis-stimulating 
agent (ESA),  is typically administered.  However,  in 
Japan,  there are patients who exhibit ESA-resistant ane-
mia,  in whom EPO administration does not improve 
the condition.  Hosokawa et al.  [2] reported that zinc 
deficiency may be a cause of ESA-resistant anemia 
because serum zinc concentrations are low in mainte-
nance dialysis patients.
Mahajan et al.  [3] reported that zinc deficiency is 
caused by impaired absorption of zinc from the intesti-
nal tract,  accompanied by decreased renal function.  A 
relatively low zinc intake may also be involved due to 
adherence to a low-protein diet,  which is commonly 
prescribed as a dietary intervention for patients with 
renal failure.  In nephrotic syndrome,  serum albumin 
levels decrease as the amount of protein lost into the 
urine increases,  which also lowers the level of pro-
tein-bound zinc.
Alternatively,  zinc deficiency may occur due to an 
increased concentration of zinc bound to amino acids,  
which is excreted in urine.  It has been reported that in 
patients with diabetic nephropathy presenting with pro-
teinuria,  serum zinc concentrations are lower than 
those in healthy people as well as patients with diabetic 
nephropathy without proteinuria [4 , 5].
Zinc is a microelement vital to the functioning of the 
human body because it is a constituent of more than 
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300 enzymes and is involved in cell division,  nucleic 
acid metabolism,  and more; it is also involved in the 
synthesis and release of insulin from pancreatic β-cells 
[6].  Zinc deficiency in vivo causes symptoms such as 
developmental disorders,  anemia,  immune deficiency,  
gonadal dysfunction,  dermatological conditions (der-
matitis and hair loss),  anorexia,  and taste disorders [7].
Polaprezinc (Promac®),  an antiulcer drug,  has been 
used as a therapeutic agent for hypozincemia because it 
contains zinc,  but this is an off-label use.  In recent 
years,  the indication of zinc acetate dehydrate (Nobelzin®),  
a drug for the treatment of Wilson’s disease,  has 
extended to the treatment of hypozincemia.  In this 
study,  we will conduct cross-sectional verification to 
determine the frequency of zinc deficiency in patients 
with CKD,  and the clinical factors associated with this 
condition.  In addition,  for CKD patients who are 
zinc-deficient,  the effect of zinc acetate dihydrate sup-
plementation on anemia and taste disorders will be 
examined in a prospective intervention trial.  The aim of 
this study is to establish a therapeutic strategy for the 
broad range of clinical symptoms associated with 
hypozincemia in patients with CKD.
Endpoints
The primary evaluation items in the intervention 
trial with zinc acetate dihydrate supplementation are the 
improvement in the patients’ serum zinc concentrations 
and zinc deficiency-related symptoms compared with 
those before the treatment.  The secondary evaluation 
items are improvement effects on the patients’ blood 
hemoglobin and serum alkaline phosphatase concen-
trations compared with those before the treatment.
Eligibility Criteria
To participate in the study,  patients will be required 
to fulfill the following criteria: (1) having chronic kid-
ney disease,  (2) aged 20-90 years,  and (3) having pro-
vided written consent to participate in the study.  The 
exclusion criteria are as follows: (1) deemed unsuitable 
for enrollment by the investigator,  e.g.,  patients with 
chronic liver failure,  chronic inflammatory bowel dis-
ease,  extreme malnutrition or poor oral intake,  and (2) 
taking polaprezinc or dietary supplements.  The inclu-
sion criteria for the zinc supplement administration are 
a serum zinc concentration < 80 μg/dL and showing 
either zinc deficiency symptoms or anemia.  The study 
enrollment period is planned from November 2017 to 
March 2019.
Treatment Methods
Study design. Study participants will be patients 
diagnosed with CKD who are being treated on an out-
patient basis at Juntendo University Hospital,  Tokyo,  
Japan.  A cross-sectional study will be conducted to 
determine the frequency of hypozincemia at each CKD 
stage (stages 1-5 and 5D).  We will also examine the 
relationship between the patients’ serum zinc concen-
tration and various clinical and laboratory find-
ings: age,  comorbid diabetes,  estimated glomerular 
filtration rate (eGFR),  presence of proteinuria,  and 
laboratory values for hemoglobin,  serum albumin,  
serum uric acid,  serum alkaline phosphatase,  iron,  
ferritin,  and copper.
After their examinations,  patients with serum zinc 
concentrations < 80 μg/dL will be requested to com-
plete a questionnaire on symptoms experienced; these 
symptoms (taste disorders,  anorexia,  dermatological 
symptoms,  or stomatitis) may be related to zinc defi-
ciency (Table 1-1).  Thereafter,  zinc acetate dihydrate 
will be administered for 24 weeks starting at an initial 
daily dose of 50 mg (Fig. 1).  Blood samples will,  as far 
as possible,  be collected on a monthly basis.  If there is 
no improvement in a patient’s serum zinc concentra-
tion,  the dosage may be increased up to a maximum of 
250 mg/day.  At the end of the treatment period,  
patients will complete the questionnaire again,  and final 
blood and urine samples will be collected (Table 1-2).
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Table 1-1　 Questionnaire on zinc deﬁciency symptoms (pre-sur-
vey)⁂
1. Currently,  do you have a taste disorder such as not being able 
to taste or feeling the same taste for whatever you eat?
0: No,  1: A little,  2: Yes
2. Please tell me whether there are the following symptoms that 
may be related to zinc deﬁciency.
1) Stomatitis
0: Not at all,  1: Almost never,  2: Sometimes,  3: Frequently
2) Prone to skin troubles (contused wound and itching)
0: Not at all,  1: Almost never,  2: Sometimes,  3: Frequently
3) Anorexia
0: No,  1: A little,  2: Yes
⁂If the patient has a symptom even to a slight degree,  select 1,  2,  
or 3.
Interventions. If transferrin saturation at the start 
of treatment is ≤ 20% and ferritin levels are ≤100 ng/mL,  
iron will be supplemented until a recommended value if 
tolerated.  Nonetheless,  zinc acetate dihydrate will be 
supplemented until anemia persists only if the patient 
can receive zinc acetate dihydrate treatment despite 
poor tolerance to iron treatment.  If a patient’s hemo-
globin levels are > 12 g/dL during the treatment,  EPO 
administration will be reduced by half.  Zinc acetate 
dihydrate,  starting from 50 mg/day,  will be adminis-
tered to the patients with serum zinc concentrations 
< 80 μg/dL.  After 4 weeks of administration,  if the 
serum zinc concentration has not reached 80 μg/dL,  
the dose will be increased by 25 mg/day.  Zinc acetate 
dihydrate may be increased up to a daily maximum of 
250 mg,  as needed.  The serum zinc target level is set at 
approx.  80-130 μg/dL.  In cases in which the patient’s 
serum zinc concentration rises above 250 μg/dL,  the 
dose will be reduced by half [8].  If the dose reduction 
fails to bring the serum zinc concentration below 
250 μg/dL,  the medication will be stopped.
Should a copper or iron deficiency be observed 
during treatment,  the administration of zinc acetate 
dihydrate will be reduced or stopped,  or the supple-
mentation of copper or iron will be initiated.  Close 
attention will be paid to copper deficiency when the 
patient’s serum zinc concentration is > 200 μg/dL or the 
serum copper concentration is around 20-30 g/dL [8].
Ethical considerations. This research protocol 
has been approved by the Institutional Review Board of 
Juntendo University Hospital.  The study will be con-
ducted in compliance with the Declaration of Helsinki 
in conjunction with our hospital’s Ethical Guidelines for 
Medical and Health Research Involving Human 
Subjects.  This study is registered in the University 
Hospital Medical Information Network Clinical Trial 
Registry (UMIN 000031655).
Statistical Considerations
Sample size. Considering that few patients pres-
ent with anemia,  the frequency of hypozincemia is also 
assumed to be low in patients with Stage 1/2 CKD.  
According to the Third National Health and Nutrition 
Examination Survey (NHANES) in the United States,  
the frequency of anemia at each CKD stage was 
Stage 3: 9%,  Stage 4: 33%,  and Stage 5: 67% [9].  
Considering that the consent to intervention cannot be 
obtained without clear zinc deficiency symptoms and 
that the relationship between the serum zinc concentra-
tion and clinical features will be examined in this 
cross-sectional study,  we estimated that a total of 500 
participants will be needed.
Statistical analysis. We will analyze continuous 
variables for each CKD stage by performing an analysis 
of variance (ANOVA),  and the association between the 
serum zinc concentration and associated clinical fea-
tures will be assessed by Spearman’s correlation coeffi-
cient.  In addition,  changes from before to after zinc 
supplement treatment will be analyzed by a paired 
t-test.  A p-value < 0.05 will be accepted as significant.  
The statistical analysis will be performed using SAS 9.4 
software (SAS Institute,  Cary,  NC,  USA).
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Table 1-2　 Questionnaire on zinc deﬁciency symptoms (post- 
survey)
1. Taste disorder
0: Worsened,  1: No change,  2: Improved
2. For the following symptoms,  potentially related to zinc deﬁ-
ciency,  could those who answered ʻyesʼ previously answer the 
questions again?
1) S ymptoms such as stomatitis  
0: Worsened,  1: No change,  2: Improved
2)  S kin troubles (contused wound and itching)  
0: Worsened,  1: No change,  2: Improved
3) A norexia  
0: Worsened,  1: No change,  2: Improved
Patients with chronic kidney disease (stages 1-5 and 5D CKD)
Obtainment of written informed consent
Measurement of circulating zinc concentration
Serum zinc concentration <80 µg/dL
Questionnaire about zinc deﬁcient symptom
If patients have anemia or　　 
zinc deﬁcient symptom 
Questionnaire about zinc deﬁcient symptom
and data analysis
Treatment by zinc acetate dihydrate (25-250 mg/day) for 24 weeks
Fig. 1　 Trial ﬂowchart
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